{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:49:12Z","timestamp":1780418952689,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recent trends in first-line transsphenoidal surgery (TSS) for prolactinoma patients aim to reduce long-term dependence on dopamine agonists (DA). Key factors linked to poor surgical outcomes include cavernous sinus invasiveness and high baseline serum prolactin (PRL) levels. Defining simple PRL threshold values to indicate invasiveness and inform treatment strategy is crucial. In this retrospective cohort study of 149 prolactinoma patients treated with first-line transsphenoidal surgery (TSS) or dopamine agonist (DA) therapy, we evaluated preoperative prolactin (PRL) levels and cavernous sinus invasion as factors associated with long-term remission. Bayesian modeling identified cohort-wide and gender-specific PRL thresholds associated with invasiveness. Preoperative PRL values strongly correlated with cavernous sinus invasion (AUROC\u2009=\u20090.95; 95% CI: 0.90\u20130.98). The cohort-wide PRL threshold was 431.9\u00a0\u00b5g\/L (95% CI: 181.1\u2013708.3\u00a0\u00b5g\/L), with gender-specific thresholds of 280.8\u00a0\u00b5g\/L (95% CI: 51.0\u2013528.2\u00a0\u00b5g\/L) for women and 1325.0\u00a0\u00b5g\/L (95% CI: 667.2\u20132582.9\u00a0\u00b5g\/L) for men. Female thresholds were lower and less affected by age and obesity, while male thresholds were influenced by these factors, particularly in young, obese men. These findings suggest that gender-specific PRL thresholds may be useful for improving specificity and sensitivity in identifying invasiveness, potentially aiding clinical decisions. Personalized treatment informed by preoperative biomarkers is essential for optimizing outcomes and reducing DA reliance, but it should be considered in conjunction with a comprehensive clinical evaluation.<\/jats:p>","DOI":"10.1038\/s41598-025-90250-6","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:23:54Z","timestamp":1742462634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations"],"prefix":"10.1038","volume":"15","author":[{"given":"Lukas","family":"Andereggen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus M.","family":"Luedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"90250_CR1","doi-asserted-by":"publisher","unstructured":"Mattogno, P. P. et al. Reappraising the role of Trans-Sphenoidal surgery in prolactin-secreting pituitary tumors. Cancers (Basel). 13 https:\/\/doi.org\/10.3390\/cancers13133252 (2021).","DOI":"10.3390\/cancers13133252"},{"key":"90250_CR2","doi-asserted-by":"publisher","unstructured":"Osorio, R. C. et al. Correlation between tumor volume and serum prolactin and its effect on surgical outcomes in a cohort of 219 prolactinoma patients. J. Neurosurg. 1\u201311. https:\/\/doi.org\/10.3171\/2022.8.JNS221890 (2022).","DOI":"10.3171\/2022.8.JNS221890"},{"key":"90250_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s13063-021-05604-y","volume":"22","author":"IM Zandbergen","year":"2021","unstructured":"Zandbergen, I. M. et al. The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials 22, 653. https:\/\/doi.org\/10.1186\/s13063-021-05604-y (2021).","journal-title":"Trials"},{"key":"90250_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva, F. F. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf). 65, 265\u2013273. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x (2006).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"90250_CR5","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou, M., Trifanescu, R., Paluzzi, A., Ahmed, S. K. & Karavitaki, N. Therapy of endocrine disease: Surgery in microprolactinomas: Effectiveness and risks based on contemporary literature. Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc. 175, R89\u201396. https:\/\/doi.org\/10.1530\/EJE-16-0087 (2016).","journal-title":"Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc."},{"key":"90250_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"Babey, M., Sahli, R., Vajtai, I., Andres, R. H. & Seiler, R. W. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 14, 222\u2013230. https:\/\/doi.org\/10.1007\/s11102-010-0283-y (2011).","journal-title":"Pituitary"},{"key":"90250_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/neuros\/nyy385","volume":"85","author":"A Micko","year":"2019","unstructured":"Micko, A., Vila, G., Hoftberger, R., Knosp, E. & Wolfsberger, S. Endoscopic transsphenoidal surgery of Microprolactinomas: A reappraisal of cure rate based on Radiological Criteria. Neurosurgery 85, 508\u2013515. https:\/\/doi.org\/10.1093\/neuros\/nyy385 (2019).","journal-title":"Neurosurgery"},{"key":"90250_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","volume":"97","author":"L Andereggen","year":"2017","unstructured":"Andereggen, L. et al. Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: Effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg. 97, 595\u2013602. https:\/\/doi.org\/10.1016\/j.wneu.2016.10.059 (2017).","journal-title":"World Neurosurg."},{"key":"90250_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12020-016-1115-2","volume":"55","author":"L Andereggen","year":"2017","unstructured":"Andereggen, L. et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55, 223\u2013230. https:\/\/doi.org\/10.1007\/s12020-016-1115-2 (2017).","journal-title":"Endocrine"},{"key":"90250_CR10","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EO-21-0038","volume":"2","author":"SMC De Sousa","year":"2022","unstructured":"De Sousa, S. M. C. Dopamine agonist therapy for prolactinomas: Do we need to rethink the place of surgery in prolactinoma management? Endocr. Oncol. 2, R31\u2013R50. https:\/\/doi.org\/10.1530\/EO-21-0038 (2022).","journal-title":"Endocr. Oncol."},{"key":"90250_CR11","doi-asserted-by":"publisher","first-page":"e1960","DOI":"10.1210\/clinem\/dgae383","volume":"109","author":"L Andereggen","year":"2024","unstructured":"Andereggen, L. & Christ, E. Letter to the editor from Andereggen and Christ: Clinical characteristics and outcomes of Prolactinomas in Children and adolescents: A large Retrospective Cohort Study. J. Clin. Endocrinol. Metab. 109, e1960\u2013e1961. https:\/\/doi.org\/10.1210\/clinem\/dgae383 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"90250_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00701-024-06213-9","volume":"166","author":"L Andereggen","year":"2024","unstructured":"Andereggen, L. et al. Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma. Acta Neurochir. (Wien). 166, 314. https:\/\/doi.org\/10.1007\/s00701-024-06213-9 (2024).","journal-title":"Acta Neurochir. (Wien)"},{"key":"90250_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12020-020-02557-1","volume":"72","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L., Frey, J. & Christ, E. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine 72, 216\u2013222. https:\/\/doi.org\/10.1007\/s12020-020-02557-1 (2021).","journal-title":"Endocrine"},{"key":"90250_CR14","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","volume":"44","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L. et al. First-line surgery in prolactinomas: Lessons from a long-term follow-up study in a tertiary referral center. J. Endocrinol. Invest. 44, 2621\u20132633. https:\/\/doi.org\/10.1007\/s40618-021-01569-6 (2021).","journal-title":"J. Endocrinol. Invest."},{"key":"90250_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-21-0293","volume":"185","author":"B Baussart","year":"2021","unstructured":"Baussart, B. et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: A cohort study. Eur. J. Endocrinol. 185, 783\u2013791. https:\/\/doi.org\/10.1530\/EJE-21-0293 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"90250_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ando.2021.11.008","volume":"83","author":"H Lasolle","year":"2022","unstructured":"Lasolle, H. et al. Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience. Ann. Endocrinol. (Paris). 83, 1\u20138. https:\/\/doi.org\/10.1016\/j.ando.2021.11.008 (2022).","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"90250_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn, S. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: A Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 19, 722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"90250_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/17446651.2022.2131531","volume":"17","author":"A Mamelak","year":"2022","unstructured":"Mamelak, A. Surgery as a first-line option for prolactinomas. Expert Rev. Endocrinol. Metab. 17, 485\u2013498. https:\/\/doi.org\/10.1080\/17446651.2022.2131531 (2022).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"90250_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao, A. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325\u2013331. https:\/\/doi.org\/10.1530\/eje.0.1480325 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"90250_CR20","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.jcte.2021.100258","volume":"24","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L. et al. Impact of primary medical or surgical therapy on prolactinoma patients\u2019 BMI and metabolic profile over the long-term. J. Clin. Transl Endocrinol. 24, 100258. https:\/\/doi.org\/10.1016\/j.jcte.2021.100258 (2021).","journal-title":"J. Clin. Transl Endocrinol."},{"key":"90250_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01569-6","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L. et al. First-line surgery in prolactinomas: Lessons from a long-term follow-up study in a tertiary referral center. J. Endocrinol. Invest. https:\/\/doi.org\/10.1007\/s40618-021-01569-6 (2021).","journal-title":"J. Endocrinol. Invest."},{"key":"90250_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: An endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"90250_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","volume":"49","author":"EA Giraldi","year":"2020","unstructured":"Giraldi, E. A. & Ioachimescu, A. G. The role of dopamine agonists in Pituitary Adenomas. Endocrinol. Metab. Clin. North. Am. 49, 453\u2013474. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.006 (2020).","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"90250_CR24","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"Luger, A. et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur. J. Endocrinol. 185, G1\u2013G33. https:\/\/doi.org\/10.1530\/EJE-21-0462 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"90250_CR25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.clineuro.2013.02.016","volume":"115","author":"H Ikeda","year":"2013","unstructured":"Ikeda, H., Watanabe, K., Tominaga, T. & Yoshimoto, T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin. Neurol. Neurosurg. 115, 1621\u20131625. https:\/\/doi.org\/10.1016\/j.clineuro.2013.02.016 (2013).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"90250_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3171\/2007.12.17635","volume":"111","author":"A Tabaee","year":"2009","unstructured":"Tabaee, A. et al. Endoscopic pituitary surgery: A systematic review and meta-analysis. J. Neurosurg. 111, 545\u2013554. https:\/\/doi.org\/10.3171\/2007.12.17635 (2009).","journal-title":"J. Neurosurg."},{"issue":"Suppl 1","key":"90250_CR27","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1530\/eje.1.02352","volume":"156","author":"MC Zatelli","year":"2007","unstructured":"Zatelli, M. C., Ambrosio, M. R., Bondanelli, M. & Uberti, E. C. D. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc. 156 (Suppl 1), S29\u2013S35. https:\/\/doi.org\/10.1530\/eje.1.02352 (2007).","journal-title":"Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc."},{"key":"90250_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","volume":"27","author":"MH Almalki","year":"2024","unstructured":"Almalki, M. H. et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: A cross-sectional multicenter study. Pituitary 27, 197\u2013203. https:\/\/doi.org\/10.1007\/s11102-024-01383-2 (2024).","journal-title":"Pituitary"},{"key":"90250_CR29","doi-asserted-by":"publisher","unstructured":"De Sousa, S. M. C. et al. Impulse Control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J. Clin. Endocrinol. Metab. 105 https:\/\/doi.org\/10.1210\/clinem\/dgz076 (2020).","DOI":"10.1210\/clinem\/dgz076"},{"key":"90250_CR30","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen, S. C. et al. Dopamine Agonist-Induced Impulse Control disorders in patients with Prolactinoma: A cross-sectional Multicenter Study. J. Clin. Endocrinol. Metab. 104, 2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"90250_CR31","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore, T. J., Glenmullen, J. & Mattison, D. R. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med. 174, 1930\u20131933. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262 (2014).","journal-title":"JAMA Intern. Med."},{"key":"90250_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu, A. G., Fleseriu, M., Hoffman, A. R., Iii, V., Katznelson, L. & T. B. & Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc. 180, 31\u201340. https:\/\/doi.org\/10.1530\/EJE-18-0682 (2019).","journal-title":"Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc."},{"key":"90250_CR33","unstructured":"Yatavelli, R. K. R. & Bhusal, K. in StatPearls (2024)."},{"key":"90250_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-04958-6","author":"L Andereggen","year":"2025","unstructured":"Andereggen, L. & Christ, E. Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas. J. Neurooncol. https:\/\/doi.org\/10.1007\/s11060-025-04958-6 (2025).","journal-title":"J. Neurooncol"},{"key":"90250_CR35","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1038\/s41598-021-89256-7","volume":"11","author":"BM Leca","year":"2021","unstructured":"Leca, B. M. et al. Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis. Sci. Rep. 11, 9801. https:\/\/doi.org\/10.1038\/s41598-021-89256-7 (2021).","journal-title":"Sci. Rep."},{"key":"90250_CR36","doi-asserted-by":"publisher","first-page":"967407","DOI":"10.3389\/fsurg.2023.967407","volume":"10","author":"L Andereggen","year":"2023","unstructured":"Andereggen, L. et al. Prolactinomas in adolescent and elderly patients-A comparative long-term analysis. Front. Surg. 10, 967407. https:\/\/doi.org\/10.3389\/fsurg.2023.967407 (2023).","journal-title":"Front. Surg."},{"key":"90250_CR37","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","volume":"11","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L. et al. Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci. Rep. 11, 5122. https:\/\/doi.org\/10.1038\/s41598-021-84606-x (2021).","journal-title":"Sci. Rep."},{"key":"90250_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1385\/ENDO:20:1-2","volume":"20","author":"M De Rosa","year":"2003","unstructured":"De Rosa, M. et al. Hyperprolactinemia in men: Clinical and biochemical features and response to treatment. Endocrine 20, 75\u201382. https:\/\/doi.org\/10.1385\/ENDO:20:1-2 (2003).","journal-title":"Endocrine"},{"key":"90250_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11102-007-0064-4","volume":"11","author":"EC Naliato","year":"2008","unstructured":"Naliato, E. C. et al. Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11, 21\u201328. https:\/\/doi.org\/10.1007\/s11102-007-0064-4 (2008).","journal-title":"Pituitary"},{"key":"90250_CR40","doi-asserted-by":"publisher","first-page":"M131","DOI":"10.1093\/geronj\/44.4.m131","volume":"44","author":"CT Sawin","year":"1989","unstructured":"Sawin, C. T., Carlson, H. E., Geller, A., Castelli, W. P. & Bacharach, P. Serum prolactin and aging: Basal values and changes with estrogen use and hypothyroidism. J. Gerontol. 44, M131\u2013135. https:\/\/doi.org\/10.1093\/geronj\/44.4.m131 (1989).","journal-title":"J. Gerontol."},{"key":"90250_CR41","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/oby.2010.150","volume":"19","author":"CM dos Santos Silva","year":"2011","unstructured":"dos Santos Silva, C. M. et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obes. (Silver Spring). 19, 800\u2013805. https:\/\/doi.org\/10.1038\/oby.2010.150 (2011).","journal-title":"Obes. (Silver Spring)"},{"key":"90250_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"Doknic, M. et al. Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol. 147, 77\u201384. https:\/\/doi.org\/10.1530\/eje.0.1470077 (2002).","journal-title":"Eur. J. Endocrinol."},{"key":"90250_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","volume":"12","author":"A Shibli-Rahhal","year":"2009","unstructured":"Shibli-Rahhal, A. & Schlechte, J. The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96\u2013104. https:\/\/doi.org\/10.1007\/s11102-008-0097-3 (2009).","journal-title":"Pituitary"},{"key":"90250_CR44","first-page":"254","volume":"136","author":"C Schmid","year":"2006","unstructured":"Schmid, C., Goede, D. L., Hauser, R. S. & Brandle, M. Increased prevalence of high body Mass Index in patients presenting with pituitary tumours: Severe obesity in patients with macroprolactinoma. Swiss Med. Wkly. 136, 254\u2013258 (2006). doi:2006\/15\/smw-10955.","journal-title":"Swiss Med. Wkly."},{"key":"90250_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki, N. et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. 65, 524\u2013529. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02627.x (2006).","journal-title":"Clin. Endocrinol."},{"key":"90250_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.beem.2013.07.002","volume":"27","author":"M Fahie-Wilson","year":"2013","unstructured":"Fahie-Wilson, M. & Smith, T. P. Determination of prolactin: the macroprolactin problem. Best Pract. Res. Clin. Endocrinol. Metab. 27, 725\u2013742. https:\/\/doi.org\/10.1016\/j.beem.2013.07.002 (2013).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"90250_CR47","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1373\/49.9.1504","volume":"49","author":"AM Suliman","year":"2003","unstructured":"Suliman, A. M., Smith, T. P., Gibney, J. & McKenna, T. J. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504\u20131509. https:\/\/doi.org\/10.1373\/49.9.1504 (2003).","journal-title":"Clin. Chem."},{"key":"90250_CR48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1258\/0004563053857969","volume":"42","author":"MN Fahie-Wilson","year":"2005","unstructured":"Fahie-Wilson, M. N., John, R. & Ellis, A. R. Macroprolactin; high molecular mass forms of circulating prolactin. Ann. Clin. Biochem. 42, 175\u2013192. https:\/\/doi.org\/10.1258\/0004563053857969 (2005).","journal-title":"Ann. Clin. Biochem."},{"key":"90250_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00701-024-06058-2","volume":"166","author":"L Andereggen","year":"2024","unstructured":"Andereggen, L., Gralla, J. & Christ, E. The diagnostic yield of inferior petrosal sinus sampling in Cushing syndrome in the era of ovine CRH shortage. Acta Neurochir. (Wien). 166, 167. https:\/\/doi.org\/10.1007\/s00701-024-06058-2 (2024).","journal-title":"Acta Neurochir. (Wien)"},{"key":"90250_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neurad.2019.05.004","volume":"48","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L. et al. Influence of inferior petrosal sinus drainage symmetry on detection of adenomas in Cushing\u2019s syndrome. J. Neuroradiol. 48, 10\u201315. https:\/\/doi.org\/10.1016\/j.neurad.2019.05.004 (2021).","journal-title":"J. Neuroradiol."},{"key":"90250_CR51","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s00701-021-04830-2","volume":"163","author":"L Andereggen","year":"2021","unstructured":"Andereggen, L. et al. Lateral one-third gland resection in Cushing patients with failed adenoma identification leads to low remission rates: Long-term observations from a small, single-center cohort. Acta Neurochir. (Wien). 163, 3161\u20133169. https:\/\/doi.org\/10.1007\/s00701-021-04830-2 (2021).","journal-title":"Acta Neurochir. (Wien)"},{"key":"90250_CR52","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ajcn\/75.6.978","volume":"75","author":"Z Mei","year":"2002","unstructured":"Mei, Z. et al. Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. Am. J. Clin. Nutr. 75, 978\u2013985 (2002).","journal-title":"Am. J. Clin. Nutr."},{"key":"90250_CR53","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp, E., Steiner, E., Kitz, K. & Matula, C. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33, 610\u2013617. https:\/\/doi.org\/10.1227\/00006123-199310000-00008 (1993). discussion 617\u2013618.","journal-title":"Neurosurgery"},{"key":"90250_CR54","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"AS Micko","year":"2015","unstructured":"Micko, A. S., Wohrer, A., Wolfsberger, S. & Knosp, E. Invasion of the cavernous sinus space in pituitary adenomas: Endoscopic verification and its correlation with an MRI-based classification. J. Neurosurg. 122, 803\u2013811. https:\/\/doi.org\/10.3171\/2014.12.JNS141083 (2015).","journal-title":"J. Neurosurg."},{"key":"90250_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger, J., Nasi-Kordhishti, I., Aboutaha, N. & Giese, S. Surgery for prolactinomas: A better choice? Pituitary 23, 45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z (2020).","journal-title":"Pituitary"},{"key":"90250_CR56","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3171\/jns.2000.93.5.0762","volume":"93","author":"RW Seiler","year":"2000","unstructured":"Seiler, R. W. & Mariani, L. Sellar reconstruction with resorbable vicryl patches, gelatin foam, and fibrin glue in transsphenoidal surgery: A 10-year experience with 376 patients. J. Neurosurg. 93, 762\u2013765. https:\/\/doi.org\/10.3171\/jns.2000.93.5.0762 (2000).","journal-title":"J. Neurosurg."},{"key":"90250_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/ncpendmet0162","volume":"2","author":"JA Wass","year":"2006","unstructured":"Wass, J. A. When to discontinue treatment of prolactinoma? Nat. Clini. Pract. Endocrinol. Metab. 2, 298\u2013299. https:\/\/doi.org\/10.1038\/ncpendmet0162 (2006).","journal-title":"Nat. Clini. Pract. Endocrinol. Metab."},{"key":"90250_CR58","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao, A. et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023\u20132033. https:\/\/doi.org\/10.1056\/NEJMoa022657 (2003).","journal-title":"N. Engl. J. Med."},{"key":"90250_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-10-0961","volume":"164","author":"X Qu","year":"2011","unstructured":"Qu, X. et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: A single-center experience with 87 consecutive cases. Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc. 164, 499\u2013504. https:\/\/doi.org\/10.1530\/EJE-10-0961 (2011).","journal-title":"Eur. J. Endocrinol.\/Eur. Fed. Endocr. Soc."},{"key":"90250_CR60","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot, G. et al. Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J. Clin. Endocrinol. Metab. 95, 1708\u20131716. https:\/\/doi.org\/10.1210\/jc.2009-1191 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"90250_CR61","doi-asserted-by":"publisher","first-page":"810219","DOI":"10.3389\/fendo.2022.810219","volume":"13","author":"M Huber","year":"2022","unstructured":"Huber, M. et al. Machine learning for outcome prediction in first-line surgery of prolactinomas. Front. Endocrinol. (Lausanne). 13, 810219. https:\/\/doi.org\/10.3389\/fendo.2022.810219 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"90250_CR62","doi-asserted-by":"publisher","unstructured":"Huber, M. et al. Gender-specific prolactin thresholds to determine prolactinoma size: A novel bayesian approach and its clinical utility. Front. Surg. 11 https:\/\/doi.org\/10.3389\/fsurg.2024.1363431 (2024).","DOI":"10.3389\/fsurg.2024.1363431"},{"key":"90250_CR63","unstructured":"Team, R. C. (Vienna, Austria, (2020)."},{"key":"90250_CR64","unstructured":"RStan: the R interface to Stan. (2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90250-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:24:00Z","timestamp":1742462640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90250-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90250"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90250-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors report no conflicts of interest concerning the materials or methods used in this study or the findings specified in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"3089 words in manuscript, 4 figure, 3 tables.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Word and figures count"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations of Scientific Reports. The study is a retrospective data project using existing data to evaluate registry data quality, and there was no any patient contact for the study, therefore there was no patient consent process. The Human Research Ethics Committee of Bern, Kantonale Ethikkommision KEK Bern, Bern, Switzerland, approved the project (KEK n\u00b0 10-10-2006 and 8-11-2006). The ethics commit KEK Bern waived the need for informed consent for this study as part of the study approval. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"9598"}}